These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6937949)

  • 1. Cefamandole against Bacteroides fragilis.
    McAllister TA
    Scand J Infect Dis Suppl; 1980; suppl 25():32-6. PubMed ID: 6937949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteroides fragilis septicemia during cefamandole therapy.
    Righter J
    Can Med Assoc J; 1981 Sep; 125(5):422, 424. PubMed ID: 7284925
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefamandole for treatment of obstetrical and gynecological infections.
    Cunningham FG; Gilstrap LC; Kappus SS
    Scand J Infect Dis Suppl; 1980; suppl 25():75-82. PubMed ID: 7010540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro activity of cefamandole against 3312 bacterial isolates. A Norwegian multicentre study.
    Digranes A; Bjorvatn B
    NIPH Ann; 1980 Dec; 3(2):141-7. PubMed ID: 7219840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of cefotaxime on anaerobes (author's transl)].
    Soussy CJ; Thibault M; Duval J
    Nouv Presse Med; 1981 Feb; 10(8):556-8. PubMed ID: 6259592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of anaerobic bacteria to five antimicrobial agents and demonstration of resistance of Bacteroides fragilis to clindamycin.
    Sofianou D; Douboyas J; Papapanagiotou J; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1982; 4(3):173-7. PubMed ID: 7121128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and synergism of cefuroxime on anaerobic bacteria.
    Thadepalli H; White DW; Bach VT
    Chemotherapy; 1981; 27(4):252-8. PubMed ID: 7249787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cooperative study of bacterial incidence and susceptibility to cefamandole and other antibiotics (author's transl)].
    de Vega JC; Pais JR; del Tánago AG
    Med Clin (Barc); 1980 May; 74(10):387-94. PubMed ID: 7412431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro and in vivo antimicrobial activity of cefuroxime cefamandole and cephalexin on freshly isolated strains of Gram-positive and Gram-negative bacteria].
    Piccolomini R; Arpini A; Di Sipio L; Minelli G
    Boll Soc Ital Biol Sper; 1981 Jul; 57(13):1450-6. PubMed ID: 7284112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic action of erythromycin and cefamandole against Bacteroides fragilis subsp. fragilis.
    Griffith RS; Brier GL; Wolny JD
    Antimicrob Agents Chemother; 1977 May; 11(5):813-6. PubMed ID: 879736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
    Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
    Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of five cephalosporins against Bacteroides fragilis.
    Ryan RW; Kwasnik I; Tilton RC
    Ann Clin Lab Sci; 1982; 12(1):32-4. PubMed ID: 6279014
    [No Abstract]   [Full Text] [Related]  

  • 15. Anaerobic bacteria in septicaemia and endocarditis.
    Nord CE
    Scand J Infect Dis Suppl; 1982; 31():95-104. PubMed ID: 6954640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.
    Aldridge KE
    Am J Surg; 1995 May; 169(5A Suppl):2S-7S. PubMed ID: 7755163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    J Chemother; 1989 Jul; 1(4 Suppl):106-7. PubMed ID: 16312326
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
    Fass RJ
    Arch Intern Med; 1980 Jun; 140(6):763-8. PubMed ID: 7387270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.